Mild Cognitive Impairment Clinical Trial
Official title:
Cognitive Remediation of Cognitive Control in Late-Life Depression
Verified date | November 2022 |
Source | UConn Health |
Contact | Seyenah Lopez |
Phone | 860-679-6189 |
seylopez[@]uchc.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants. The investigators are also interested in whether participating in the treatment will result in changes to brain activity measured with magnetic resonance imaging (MRI).
Status | Recruiting |
Enrollment | 138 |
Est. completion date | July 31, 2024 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - ability to read and write in English - current major or mild depression despite ongoing treatment - under the care of a physician who prescribes medication for depression - currently treated with an antidepressant for at least 8 weeks Exclusion Criteria: - psychosis - other psychiatric disorders (except personality & generalized anxiety disorders) - substance use disorders in the prior year - clinical diagnosis of dementia - neurological disorders (e.g., stroke, epilepsy, brain injury with loss of consciousness > 30 minutes, brain tumors, demyelinating diseases) - corrected visual acuity < 20/70 or color blindness |
Country | Name | City | State |
---|---|---|---|
United States | UConn Health | Farmington | Connecticut |
Lead Sponsor | Collaborator |
---|---|
UConn Health | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in attention / cognitive flexibility as measured by the Trail Making Part B test | time to complete alpha-numeric sequencing | Pre-treatment and six weeks later when treatment has ended | |
Primary | Change in depression symptom severity as measured with the Montgomery Asberg Depression Rating Scale (MADRS) | depression rating scale | Pre-treatment and six weeks later when treatment has ended | |
Secondary | Change in verbal learning as measured with the California Verbal Learning Test (CVLT) Total Learning | number of words recalled over 5 trials and spontaneous semantic organization of those words | Pre-treatment and six weeks later when treatment has ended | |
Secondary | Change in attention processing speed as measured with the Flanker Test of Response Inhibition from the NIH Cognitive Toolbox | computerized test of response inhibition, speed of responding | Pre-treatment and six weeks later when treatment has ended | |
Secondary | Change in self-reported depressive symptoms measured with the Carroll Depression Rating Scale | self-report of depression symptoms | Pre-treatment and six weeks later when treatment has ended | |
Secondary | Change in problem solving/speed/spatial memory as measured with the NIH Toolbox fluid composite scales | computerized picture memory, simple processing speed, problem solving/mental flexibility | Pre-treatment and six weeks later when treatment has ended |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |